Ruth Röck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruth Röck has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Eduard Stefan
University of Innsbruck
3 shared publications - Florian Enzler
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck , Innrain 80/82, Innsbruck 6020 , Austria
3 shared publications - Jakob Troppmair
Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Omar Torres-Quesada
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria
3 shared publications Andrea Raffeiner
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria
2 shared publications- Andreas Feichtner
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck
2 shared publications
Latest Publications
- Open Access
- 12 August 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (6) , 1023-1036
Precise, predictable genome integrations by deep-learning-assisted design of microhomology-based templates
Precise CRISPR-based DNA integration and editing remain challenging, largely because of insufficient control of the repair process. We find that repair at the genome–cargo interface is predictable by deep learning models and adheres to sequence-context-specific rules. On the basis of in silico predictions, we devised a strategy of base-pair tandem repeat repair arms matching microhomologies at double-strand breaks. These repeat homology arms promote frame-retentive cassette integration and reduce deletions both at the target site and within the transgene. We demonstrate precise integrations at 32 loci in HEK293T cells. Germline-transmissible transgene integration and endogenous protein tagging in Xenopus and adult mouse brains demonstrated precise integration during early embryonic cleavage and in nondividing, differentiated cells. Optimized repair arms also facilitated small edits for scarless single-nucleotide or double-nucleotide changes using oligonucleotide templates in vitro and in vivo. We provide the design tool Pythia to facilitate precise genomic integration and editing for experimental and therapeutic purposes for a wide range of target cell types and applications.
- 12 August 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (6) , 1023-1036
Open AccessPrecise, predictable genome integrations by deep-learning-assisted design of microhomology-based templates
Precise CRISPR-based DNA integration and editing remain challenging, largely because of insufficient control of the repair process. We find that repair at the genome–cargo interface is predictable by deep learning models and adheres to sequence-context-specific rules. On the basis of in silico predictions, we devised a strategy of base-pair tandem repeat repair arms matching microhomologies at double-strand breaks. These repeat homology arms promote frame-retentive cassette integration and reduce deletions both at the target site and within the transgene. We demonstrate precise integrations at 32 loci in HEK293T cells. Germline-transmissible transgene integration and endogenous protein tagging in Xenopus and adult mouse brains demonstrated precise integration during early embryonic cleavage and in nondividing, differentiated cells. Optimized repair arms also facilitated small edits for scarless single-nucleotide or double-nucleotide changes using oligonucleotide templates in vitro and in vivo. We provide the design tool Pythia to facilitate precise genomic integration and editing for experimental and therapeutic purposes for a wide range of target cell types and applications.
- 1 July 2022
- Published by American Physiological Society in Physiology
- Vol. 37 (4) , 207-215
Kidney Development: Recent Insights from Technological Advances
The kidney is a complex organ, and how it forms is a fascinating process. New technologies, such as single-cell transcriptomics, and enhanced imaging modalities are offering new approaches to understand the complex and intertwined processes during embryonic kidney development.
- 1 July 2022
- Published by American Physiological Society in Physiology
- Vol. 37 (4) , 207-215
Kidney Development: Recent Insights from Technological Advances
The kidney is a complex organ, and how it forms is a fascinating process. New technologies, such as single-cell transcriptomics, and enhanced imaging modalities are offering new approaches to understand the complex and intertwined processes during embryonic kidney development.
- Open Access
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (49) , 31105-31113
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies
Significance: The pharmaceutical targeting of mutated BRAF has shown promising clinical outcomes in patients with melanoma. However, more than 300 reported BRAF patient mutations and the occurrence of a kinase-drug resistance mechanism hamper patient-oriented therapies. We have developed an extendable and cell-based kinase conformation reporter platform (KinCon) to predict and compare the effect of kinase drugs. We systematically evaluated drug efficacies by assessing KinCon reporter dynamics in response to different drugs and patient mutations. Our findings suggest that FDA-approved melanoma inhibitors may have the potential to block non-V600E–mutated BRAF activities also in non–small-cell lung cancers (NSCLC). We assume that widespread analyses of KinCon:drug interactions may assist in the future in identifying patient mutation–specific and thus more effective kinase inhibitors.
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (49) , 31105-31113
Open AccessMutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies
Significance: The pharmaceutical targeting of mutated BRAF has shown promising clinical outcomes in patients with melanoma. However, more than 300 reported BRAF patient mutations and the occurrence of a kinase-drug resistance mechanism hamper patient-oriented therapies. We have developed an extendable and cell-based kinase conformation reporter platform (KinCon) to predict and compare the effect of kinase drugs. We systematically evaluated drug efficacies by assessing KinCon reporter dynamics in response to different drugs and patient mutations. Our findings suggest that FDA-approved melanoma inhibitors may have the potential to block non-V600E–mutated BRAF activities also in non–small-cell lung cancers (NSCLC). We assume that widespread analyses of KinCon:drug interactions may assist in the future in identifying patient mutation–specific and thus more effective kinase inhibitors.
- 1 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (5_Suppleme) , B45
Abstract B45: Surveillance of RAS-RAF dynamics in vivo: Tracking activity conformations and drug-induced interactions
Live-cell recordings of protein conformations and interactions yield novel mechanistic insights into physiologic and pathologic protein functions. We have developed an adaptable and genetically encoded bioluminescence-based biosensor platform to precisely measure signaling dynamics of full-length RAS GTPases and RAF kinases upon physiologic pathway activation, post-translational modifications, mutagenesis, and drug binding. We have recorded the impact of both patient mutations and bioactive small-molecule binding on kinase conformations and binary interactions of GTP-loaded H, N, KRAS with kinases such as RAF. Systematic profiling of αC-helix-OUT BRAF inhibitors (BRAFi) vemurafenib, dabrafenib, encorafenib, and PLX8394 using the BRAF reporter reporter platform (displaying 10 different patient mutations) revealed differences in drug specificities and efficacies. Unexpectedly, the αC-helix-OUT BRAFi engagement with the catalytic pocket of mutated BRAF stabilized an inactive and intermediate full-length kinase conformation, which provoked the enhancement of binary RAS:RAF interactions. We showed that the interference with RAS interactions and nanoclustering has the potential to antagonize the sequential formation of drug-induced tetrameric RAS:RAF complexes. Recently, we have bioengineered a reporter toolbox for direct in vivo recordings of RAS activity conformations. First, we demonstrated that the wild-type RAS reporter—expressed at levels far below endogenous RAS proteins—responds to physiologic pathway activation. Second, we showed that hot-spot RAS mutations display a similar effect on the intramolecular dynamics. The systematic implementation, combination, and advancement of the GTPase and kinase reporter platform have the potential to be used to identify novel means for regulating or perturbing RAS-RAF-ERK signaling in vivo. Citation Format: Ruth Röck, Johanna Mayrhofer, Omar Torres-Quesada, Florian Enzler, Jakob Troppmair, Eduard Stefan. Surveillance of RAS-RAF dynamics in vivo: Tracking activity conformations and drug-induced interactions [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr B45.
- 1 May 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (5_Suppleme) , B45
Abstract B45: Surveillance of RAS-RAF dynamics in vivo: Tracking activity conformations and drug-induced interactions
Live-cell recordings of protein conformations and interactions yield novel mechanistic insights into physiologic and pathologic protein functions. We have developed an adaptable and genetically encoded bioluminescence-based biosensor platform to precisely measure signaling dynamics of full-length RAS GTPases and RAF kinases upon physiologic pathway activation, post-translational modifications, mutagenesis, and drug binding. We have recorded the impact of both patient mutations and bioactive small-molecule binding on kinase conformations and binary interactions of GTP-loaded H, N, KRAS with kinases such as RAF. Systematic profiling of αC-helix-OUT BRAF inhibitors (BRAFi) vemurafenib, dabrafenib, encorafenib, and PLX8394 using the BRAF reporter reporter platform (displaying 10 different patient mutations) revealed differences in drug specificities and efficacies. Unexpectedly, the αC-helix-OUT BRAFi engagement with the catalytic pocket of mutated BRAF stabilized an inactive and intermediate full-length kinase conformation, which provoked the enhancement of binary RAS:RAF interactions. We showed that the interference with RAS interactions and nanoclustering has the potential to antagonize the sequential formation of drug-induced tetrameric RAS:RAF complexes. Recently, we have bioengineered a reporter toolbox for direct in vivo recordings of RAS activity conformations. First, we demonstrated that the wild-type RAS reporter—expressed at levels far below endogenous RAS proteins—responds to physiologic pathway activation. Second, we showed that hot-spot RAS mutations display a similar effect on the intramolecular dynamics. The systematic implementation, combination, and advancement of the GTPase and kinase reporter platform have the potential to be used to identify novel means for regulating or perturbing RAS-RAF-ERK signaling in vivo. Citation Format: Ruth Röck, Johanna Mayrhofer, Omar Torres-Quesada, Florian Enzler, Jakob Troppmair, Eduard Stefan. Surveillance of RAS-RAF dynamics in vivo: Tracking activity conformations and drug-induced interactions [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr B45.
- Open Access
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (8) , eaav8463
BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
Patient mutation–specific BRAF inhibitors alter full-length kinase conformations and promote interactions with GTP-loaded RAS.
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (8) , eaav8463
Open AccessBRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
Patient mutation–specific BRAF inhibitors alter full-length kinase conformations and promote interactions with GTP-loaded RAS.